{"entity":{"id":"miles-prince","kind":"person","name":"H. Miles Prince","aka":[],"tldr":"Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.","summary":"Miles Prince is a haematologist at the Peter MacCallum Cancer Centre and Epworth Healthcare in Melbourne. He was first author of the 2017 Lancet report of ALCANZA, the international phase 3 trial in which brentuximab vedotin produced more lasting responses than physician's choice of methotrexate or bexarotene in previously treated CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, leading to the drug's approval in this setting.","asOf":"2026-09-18","links":[],"tags":["lymphoma","trialist"],"related":[],"cancers":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["alcanza"],"people":[],"bottlenecks":[],"keyPapers":["paper-alcanza-brentuximab-vedotin-lancet-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne","institutionId":"peter-mac","specialisms":["Cutaneous T-cell lymphoma","Multiple myeloma","Novel agents in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prince%5BAuthor%5D"}],"papers":[]},"route":"/people/miles-prince/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"trial":[{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/"}],"paper":[{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/"}]}}